VCYT

Veracyte Inc

Add to Watchlist

Advanced Chart

30.220

+0.18(0.599%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

30.630

Open

30.460

VWAP

30.29

Vol

1.15M

Mkt Cap

2.38B

Low

29.845

Amount

34.76M

EV/EBITDA(TTM)

34.13

Total Shares

78.67M

2.06B

EV/OCF(TTM)

22.01

P/S(TTM)

5.01

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

124.53M

+7.48%

0.319

-3.48%

131.04M

+10.46%

0.371

+3.17%

126.91M

+10.87%

0.274

-11.58%

Estimates Revision

The market is revising Upward the revenue expectations for Veracyte, Inc. (VCYT) for FY2025, with the revenue forecasts being adjusted by 1.04% over the past three months. During the same period, the stock price has changed by 4.21%.

Revenue Estimates for FY2025

Revise Upward

+1.04%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+9.15%

In Past 3 Month

Stock Price

Go Up

+4.21%

In Past 3 Month

7 Analyst Rating

33.02% Upside

Wall Street analysts forecast VCYT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCYT is 40.20 USD with a low forecast of 29.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

1 Sell

Moderate Buy

33.02% Upside

Current: 30.220

Low

29.00

Averages

40.20

High

45.00

33.02% Upside

Current: 30.220

Low

29.00

Averages

40.20

High

45.00

Morgan Stanley

Tejas Savant

Underweight

downgrade

$29 -> $28

2025-08-08

Reason

Morgan Stanley

Tejas Savant

Price Target

$29 -> $28

2025-08-08

downgrade

Underweight

Reason

Morgan Stanley analyst Tejas Savant lowered the firm's price target on Veracyte to $28 from $29 and keeps an Underweight rating on the shares. The company reported a solid Q2 beat on continued Decipher/Afirma momentum leading to a 2025 guidance raise, the analyst tells investors in a research note. The firm added that Veracyte's pipeline is promising an represents substantial opportunity, though meaningful upside remains a 2027+ dynamic.

UBS

Buy

downgrade

$49 -> $42

2025-05-08

Reason

UBS

Price Target

$49 -> $42

2025-05-08

downgrade

Buy

Reason

UBS lowered the firm's price target on Veracyte to $42 from $49 and keeps a Buy rating on the shares. UBS sees durable growth in Veracyte's core products, as well as long-term growth potential from minimal residual disease testing, the analyst tells investors in a research note.

Guggenheim

Subbu Nambi

Strong Buy

Maintains

$45 → $37

2025-04-09

Reason

Guggenheim

Subbu Nambi

Price Target

$45 → $37

2025-04-09

Maintains

Strong Buy

Reason

Guggenheim lowered the firm's price target on Veracyte to $37 from $45 and keeps a Buy rating on the shares. The firm adjusted its 2025 revenue and test volumes based on recent management commentary, updated its model for the latest 10K release post-earnings and revised its price target to reflect multiple compression in the peer group.

Stephens & Co.

Mason Carrico

Buy

Reiterates

$45

2025-03-26

Reason

Stephens & Co.

Mason Carrico

Price Target

$45

2025-03-26

Reiterates

Buy

Reason

Craig-Hallum

John Wilkin

Strong Buy

Initiates

$45

2025-03-20

Reason

Craig-Hallum

John Wilkin

Price Target

$45

2025-03-20

Initiates

Strong Buy

Reason

Craig-Hallum initiated coverage of Veracyte with a Buy rating and $45 price target.

Needham

Mike Matson

Strong Buy

Reiterates

$51

2025-02-25

Reason

Needham

Mike Matson

Price Target

$51

2025-02-25

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Veracyte Inc (VCYT.O) is 23.24, compared to its 5-year average forward P/E of -21.41. For a more detailed relative valuation and DCF analysis to assess Veracyte Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-21.41

Current PE

23.24

Overvalued PE

1292.18

Undervalued PE

-1335.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-58.71

Current EV/EBITDA

17.97

Overvalued EV/EBITDA

88.58

Undervalued EV/EBITDA

-206.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

7.83

Current PS

4.55

Overvalued PS

12.63

Undervalued PS

3.02